Helmut R. Salih

Otfried Müller Str. 10
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 170 publications

The challenge of patient recruitment into early phase clinical trials: Is time-effective academic translational research feasible? Lessons from a phase I/II trial in patients with B-cell deficiencies.

The challenge of patient recruitment into early phase clinical trials: Is time-effective academic translational research feasible? Lessons from a phase I/II trial in patients with B-cell deficiencies.

Journal: Frontiers in medicine

Published: March 31, 2026

Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.

Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.

Journal: Frontiers in immunology

Published: January 23, 2026

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer.

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer.

Journal: ImmunoTargets and therapy

Published: October 28, 2025

Generation and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia.

Generation and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia.

Journal: Frontiers in immunology

Published: October 20, 2025

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Journal: The Lancet. Haematology

Published: September 18, 2025

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Journal: Clinical therapeutics

Published: June 23, 2025

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.

Journal: Journal of translational medicine

Published: March 27, 2025

Bispecific antibodies in prostate cancer therapy

Bispecific antibodies in prostate cancer therapy

Journal: Urologie (Heidelberg, Germany)

Published: March 10, 2025

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia.

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia.

Journal: Frontiers in immunology

Published: January 16, 2025

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Journal: Frontiers in immunology

Published: August 18, 2024

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

Journal: Frontiers in oncology

Published: July 02, 2024

Targeting CD276 for T cell-based immunotherapy of breast cancer.

Targeting CD276 for T cell-based immunotherapy of breast cancer.

Journal: Journal of translational medicine

Published: June 14, 2024

Showing 1-12 of 170

Last Updated: 09/26/2026